OpenAI Acquires Orchestra Bio to Enhance Biotech Capabilities
On October 20, 2026, OpenAI announced the acquisition of Orchestra Bio, a four-year-old AI biotechnology startup. The terms were not disclosed, but Orchestra had raised approximately $20 million by 2025 from investors including Andreessen Horowitz and Atria. Orchestra's technology focuses on using AI to streamline drug discovery operations for biotech companies. OpenAI plans to integrate Orchestra’s team and tools into its Rosalind platform, an AI model designed for life sciences research, as well as the Rosalind Workbench tool used by researchers. OpenAI has already secured major clients like Moderna and Novo Nordisk for Rosalind. The acquisition reflects a broader trend of leading AI labs expanding their influence across key industries such as pharmaceuticals. This move highlights growing concerns in the startup ecosystem about large AI firms potentially competing with smaller companies through aggressive feature development or acquisitions.
Topics: AI biotech OpenAI Orchestra Bio
Read the full article at TechCrunch
Part of the story OpenAI Acquires Orchestra Bio to Enhance Biotech Capabilities (2 articles)